FDA Warning Letters to GLP-1 Compounders and Telehealth Firms: 2026 Update

In 2025 and 2026, the FDA issued warning letters to more than 30 telehealth firms and compounding operations for making misleading claims about compounded GLP-1 medications. These letters reveal the specific practices the agency considers problematic — and understanding them helps patients identify providers who are operating properly.

What the Warning Letters Targeted

Claiming compounded products are "identical" to branded drugs

The most common violation. Multiple firms told patients their compounded semaglutide was "the same as" or "identical to" Ozempic or Wegovy. The FDA's position is clear: compounded drugs are NOT FDA-approved, have NOT undergone the same safety and efficacy review, and should NEVER be marketed as interchangeable with approved products.

Misrepresenting FDA approval status

Some providers used language that implied their compounded products had FDA approval or endorsement. Others used Novo Nordisk or Eli Lilly trademarks without authorization, creating the impression of brand association.

Making unsubstantiated efficacy claims

Claims like "lose 20% of your body weight" using compounded GLP-1s — without clarifying that this data comes from branded product trials, not studies of the compounded formulation — violate FDA marketing regulations.

Quality and safety concerns

Novo Nordisk's litigation alleged that some compounded semaglutide samples contained impurity levels as high as 86%. While contested by the compounding industry, these allegations contributed to the FDA's regulatory posture.

What This Means for You as a Patient

Warning letters are not bans. Most providers who received them corrected their marketing language and continue operating. But the pattern tells you what the FDA considers the line between legitimate compounding and problematic behavior.

Good signs in a provider:

• Clearly states medications are compounded and NOT FDA-approved
• Never claims equivalence to branded products
• Uses its own brand identity, not Ozempic/Wegovy trademarks
• Provides honest information about what compounding is and isn't